The discovery that 1-methyl-4-phenylpyridinium (MPP + ) selectively destroys dopaminergic neurons and causes Parkinson's disease (PD) symptoms in mammals has strengthened the environmental hypothesis of PD. The current model for the dopaminergic toxicity of MPP + is centered on the uptake into dopaminergic neurons, accumulation into the mitochondria, inhibition of the complex-I leading to ATP depletion, increased reactive oxygen species (ROS) production, and apoptotic cell death. However, some aspects of this mechanism and the details of the cellular and mitochondrial accumulation of MPP + are still poorly understood. The aim of this study was to characterize a structural and functional MPP + mimic which is suitable to study the cellular distribution and mitochondrial uptake of MPP + in live cells and use it to identify the molecular details of these processes to advance the understanding of the mechanism of the selective dopaminergic toxicity of MPP + . Here we report the characterization of the fluorescent MPP + derivative, 1-methyl-4-(4'-iodophenyl)pyridinium (4'I-MPP + ), as a suitable candidate for this purpose. Using this novel probe, we show that cytosolic/mitochondrial Ca 2+ play a critical role through sodium-calcium exchanger (NCX) in the mitochondrial and cellular accumulation of MPP + suggesting for the first time that MPP + and related mitochondrial toxins may also exert their toxic effects through the perturbation of Ca 2+ homeostasis in dopaminergic cells. We also found that the specific mitochondrial NCX (mNCX) inhibitors protect dopaminergic cells from the MPP + and 4'I-MPP + toxicity, most likely through the inhibition of the mitochondrial uptake, which could potentially be exploited for the development of pharmacological agents to protect the central nervous system (CNS) dopaminergic neurons from PD-causing environmental toxins. S2 Fig. Effects of Benzamil, Verapamil, FFA, and ruthenium red on the MN9D mitochondrial uptake of 4'I-MPP + .
Introduction
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra, a region in the midbrain [1, 2] . PD is a chronic and progressive disorder in mid to late ages and characterized by the motor impairment and autonomic dysfunction. The exact cause(s) of dopaminergic neuronal death in PD is not fully understood, but environmental factors are proposed to play a role. The discovery that the synthetic chemical, 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP), recapitulates major pathophysiological characteristics of PD provided the strongest support for the possible environmental contribution to the etiology of PD. Lipophilic MPTP crosses the blood brain barrier and undergoes monoamine oxidase-B catalyzed oxidation in glial cells to produce the terminal toxin, 1-methyl-4-phenylpyridinium (MPP + ) [3] . Numerous previous in vivo and in vitro studies have shown that the metabolite MPP + , not the parent compound, MPTP, selectively destroys dopaminergic neurons [4] . Therefore, MPTP/MPP + has been widely used as a convenient model to study the mechanisms of specific dopaminergic cell death in PD and in the development of therapeutic and preventive strategies [5] [6] [7] .
The currently accepted mechanism for the selective dopaminergic toxicity of MPP + consists several key steps including specific uptake of extracellular MPP + into dopaminergic cells through the plasma membrane dopamine transporter (DAT), active mitochondrial accumulation of cytosolic MPP + , inhibition of the complex-I leading to the intracellular ATP depletion, increased reactive oxygen species (ROS) production and apoptotic cell death [8, 9] . Although many aspects of this mechanism have been widely tested and accepted, a number of recent studies have challenged the proposal that the selective in vivo toxicity of MPP + towards dopaminergic cells is due to the specific uptake through DAT, in favor of the possibility that dopaminergic neurons may inherently possess a high propensity towards mitochondrial toxin-mediated ROS production [10, 11] . In addition, the molecular details of the mitochondrial accumulation of MPP + is not fully explored or well understood.
Since MPP + is the most widely used model to study the environmental contributions to the etiology of PD at present, [5] a better understanding of the mechanisms of cellular/mitochondrial accumulation and the selective dopaminergic toxicity of MPP + at the molecular level is of importance. Certainly, availability of structural and toxicological MPP + mimics could provide additional information on the cellular distribution, mitochondrial accumulation, and key cellular factors associated with these processes to advance the understanding of the mechanism of the selective dopaminergic cell toxicity of MPP + at the molecular level [12, 13] . In the present study, we have synthesized and characterized 4'I-MPP + as a fluorescent MPP + mimic with desirable toxicological and photophysical properties that could be used to further explore the details of cellular and mitochondrial accumulations of MPP + in live cells to advance the understanding of the mechanism of the selective dopaminergic toxicity of MPP + . Using this novel probe, we demonstrate that intracellular Ca 2+ and the mitochondrial and plasma membrane sodium-calcium exchangers (NCX) play a role in the cellular and mitochondrial accumulation of MPP + . Based on these findings, we propose that MPP + and related mitochondrial toxins may also exert their toxic effects through the perturbation of cellular Ca 2+ homeostasis in dopaminergic cells. In addition, the finding that specific mitochondrial sodium-calcium exchanger (mNCX) inhibitors inhibit the mitochondrial accumulation of MPP + and protect dopaminergic cells from toxicity could potentially be used to develop effective pharmacological agents to protect the central nervous system (CNS) dopaminergic neurons from PD-causing environmental toxins.
Materials and methods

Cell lines and material
The mouse hybridoma cell line MN9D [PRID: CVCL_M067 [14] ] was graciously provided by Dr. UV-visible spectra were recorded on a Cary Bio 300 UV-visible spectrophotometer (Varian Inc., Palo Alto, CA). Fluorescence emission spectra were recorded on a Jobin Yvon-Spex Tau-3 spectrophotometer (USA Instruments, Inc., Aurora, OH). The uptake rates of MPP + and 4'I-MPP + were determined by HPLC-UV using a solvent system of 48% aqueous buffer containing 20 mM Na 3 PO 4 , 20 mM CH 3 CO 2 Na, 30 mM triethylamine, 1.7 mM 1-octanesulfonic acid sodium salt, pH 7.0, and 52% CH 3 CN at a flow rate of 0.8 mL/min with the UV detection at 295 and 310 nm, respectively. All fluorescence light microscopic experiments were carried out using a Nikon ECLIPS Ti microscope equipped with a Nikon S FLURO 40X objective (Nikon Instrument Inc., Melville, NY). Intracellular ROS levels in live cells were monitored using a Leica [16] confocal fluorescence microscope equipped with a 40X objective (Leica Microsystems Inc., Buffalo Grove, IL).
Methods
Cell culture
MN9D [14] and HepG2 [17] cells were cultured in 100 mm 2 Falcon tissue culture plates in DMEM-HCO 3supplemented with 10% fetal bovine serum, 50 g/mL streptomycin, and 50 IU/mL penicillin at 37 °C in a humidified atmosphere of 7% CO 2 . Cells were cultured to about 70-80% confluence and then seeded into glass-bottomed culture plates (for imaging studies) or 12-or 96-well plates depending on the experiment and grown to about 70-80% confluence (usually two days) unless otherwise stated.
Differentiation of MN9D cells
The differentiation of MN9D cells was carried out with 1.0 mM sodium n-butyrate according to the published procedure of Choi et al [14] . Briefly, MN9D cells were grown in DMEM-HCO 3 - containing 10% fetal bovine serum with 1.0 mM sodium butyrate at 37 °C in a humidified atmosphere of air with 7% CO 2 for 3 days at which time the media was replaced with fresh media containing 1.0 mM sodium n-butyrate and incubated for an additional 3 days. The progress of differentiation was judged by observing the expected morphological changes. All differentiated cells were used in appropriate experiments after the 6 th day of differentiation.
Time dependency of cellular uptakes of MPP + and 4'I-MPP +
Cells were seeded into 12-well plates at 0.25 x 10 6 cells/well and grown 2-3 days to about 70- 
Measurement of cell viabilities
Cell viability was determined by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)] assay [19] . Briefly, cells were seeded on 96-well plates and allowed to grow to about 70-80% confluence. Prior to the experiment, culture media was replaced with DMEM-HCO 3 - containing desired concentrations of MPP + or 4'I-MPP + and incubated for 16 h at 37 °C. After the incubation, 10 μL of 5 mg/mL MTT solution was added to each well and incubated for 2 h at 37 °C. The resulting formazan was solubilized by the addition of 210 L detergent solution [50% DMF/H 2 O (v/v), 20% SDS (w/v)] followed by incubation at 37 °C for 12 h. The cell viabilities were determined by quantifying solubilized formazan by measuring the difference in the absorbance at 570 nm and 650 nm [20] . Results were expressed as % viability of MPP + or 4'I-MPP + treated cells with respect to control cells, which were treated under the same conditions except in the absence of the MPP + or 4'I-MPP + .
Measurement of mitochondrial complex-I inhibition
Isolated rat brain mitochondria were lysed by freeze-thawing in hypotonic media containing 25 mM K 3 PO 4 and 5 mM MgCl 2 , pH 7.2 [21] . 
Measurement of intracellular ATP levels
Cells grown in 12-well plates were treated with 100 μM MPP + or 4'I-MPP + in KRB-HEPES for 6 h at 37 °C. After the treatments, cells were suspended in 1 mL of ice-cold KRB-HEPES and 50 μL samples were withdrawn for protein quantification. The remaining cell suspensions were centrifuged for 3 min at 3,500 x g at 4 °C and the cell pellets were treated with 1 mL of lysis buffer (0.1 M Tris, 1 % Triton X-100, pH 7.5) for 2 min and centrifuged at 3,500 x g for 3 min to remove the cell debris. The ATP contents of the supernatants were measured using a fluorometric ATP assay kit (BioVision, Milpitas CA, USA) following the manufactures guidelines . All ATP levels were normalized to the protein content of each sample.
Measurement of intracellular Reactive Oxygen Species (ROS)
Cells grown in 12-well plates were incubated with 10 M DCFH-DA in KRB-HEPES for 1 h. 
DCFH
Measurement of MPP + and 4'I-MPP + uptake into isolate MN9D cell mitochondria
Intact mitochondria were isolated from MN9D cells according to the published procedure of Frezza et al [24] . The isolated intact mitochondrial preparations were suspended in KCl buffer and aliquots (5 L) were withdrawn for protein determination. Desired amounts of mitochondrial suspensions were incubated with 400 μM MPP + or 4'I-MPP + in KCl buffer for 45 min at 37 °C.
After the incubation, incubates were centrifuged at 7,000 x g at 4 °C for 10 min and the mitochondrial pellets were treated with 75 μL of 0. 
Effects of MPP + and 4'I-MPP + on the mitochondrial membrane potentials
MN9D or HepG2 cells grown in glass-bottomed plates were treated with 50 nM TMRM (AnaSpec, Fremont CA, USA) in KRB-HEPES for 45 min in the dark [25] . After mounting on the stage of 
Protein determination
Protein contents of various cell preparations were determined by the method of Bradford using bovine serum albumin (BSA) as the standard [26] . Aliquots of (50 μL) of cell suspensions were incubated with Bradford protein reagents (950 μL) for 10 min and absorbance at 595 nm were recorded. The absorbance readings were converted to the corresponding protein concentrations using a standard curve constructed employing BSA.
Statistical analyses
All data are averages of three or more replicates of a single experiment and presented as mean ± SD (all the experiments were carried out multiple times and the representative data from a single experiment are shown). To correct for the minor variations in color development in the MTT assay of cell viability, all the absorbance values were converted to percentages of controls, which were treated under the same conditions, except that MPP + and 4'I-MPP + were excluded from the incubations. All quantitative data i.e. uptake, ATP, and ROS levels were normalized to the protein content of individual samples to correct for the cell density variations. P values for pair-wise comparisons were calculated by two-tailed Student's T-test. For all the data a level of p<0.05 was considered statistically significant.
Technical statement
Due to the high toxicity and obvious health hazards of MPP + and 4'I-MPP + , extreme caution was used in their handling in accordance with published procedures [27] .
Results
Photophysical properties of 4'I-MPP +
4'I-MPP + (Fig 1A) showed a characteristic UV-Vis spectral analysis of absorption band at ~313 nm and a moderately intense fluorescence band with the excitation and emission maxima at 320 and 430 mm in PBS, respectively ( Fig 1B and 1C) . Standard photochemical studies showed that 
4'I-MPP + and MPP + causes mitochondrial complex-I Inhibition, ATP depletion, increased intracellular ROS production causing apoptotic cell death in dopaminergic cells
The effect of 4'I-MPP + on the NADH-ubiquinone oxidoreductase (complex-I) activity of rat brain mitochondrial membrane fragments was determined using the ubiquinone dependent NADH-oxidation assay [22] . The inhibition of complex-I was measured by measuring the decrease in absorbance due to the ubiquinone dependent oxidation of NADH at 340 nm as a function of time.
Under the standard assay conditions, rotenone, a well-characterized specific and potent complex-I inhibitor [28] inhibited about 90% of the NADH oxidation activity at 10 M concentration confirming the suitability of the assay for specific complex-I activity measurements ( Fig 2B) .
Under similar conditions, 4'I-MPP + and MPP + showed 46% and 21% inhibition of the complex-I activity at 200 M concentrations, respectively, suggesting that 4'I-MPP + is a better complex-I inhibitor than MPP + (Fig 2B) . In addition, both MPP + and 4'I-MPP + deplete intracellular ATP levels in both MN9D and HepG2 cells, with 4'I-MPP + showing a more pronounced effect in comparison to MPP + in MN9D cells ( Fig 2C) . Furthermore, both MPP + and 4'I-MPP + treatments increase ROS production [measured by the ROS sensitive fluorescent probe DCFH-DA [29] ] specifically in MN9D ( Fig 3A) , but not in HepG2 cells. Fluorescence live cell imaging experiments also show the 4'I-MPP + -mediated intracellular ROS production in MN9D ( Fig 3B) .
4'I-MPP + -mediated MN9D apoptotic cell death is associated with the characteristic apoptotic cell
death pathway including cell shrinkage and chromatin condensation (as indicated by the increase of the nuclear DAPI fluorescence in toxin treated cells), similar to the MPP + ( Fig 3C) . (Fig 4A) . Experiments with isolated mitochondria further show that while both MPP + and 4'I-MPP + are taken up into isolated MN9D cell mitochondria effectively, the rate of 4'I-MPP + uptake was faster than that of MPP + (Fig 4B) . The mitochondrial accumulations of both MPP + and 4'I-MPP + are also associated with a depolarization of the mitochondrial membrane potential (Fig 4C and D) [18] . In parallel to the uptake characteristics, 4'I-MPP + was more effective in depolarizing the mitochondrial membrane potential in comparison to MPP + . 
Effects of extra-cellular and extra-mitochondrial Ca 2+ and mNCX and inhibitors on the mitochondrial accumulation of MPP +
Previous studies have indicated that intracellular Ca 2+ may play a role in the cellular [32, 33] and mitochondrial [34] accumulation of MPP + . As shown from the data in Fig 6A, 500-1000 nM Ca 2+ in the incubation media inhibits the 4'I-MPP + uptake into mitochondria by about 40-60% suggesting that extra-mitochondrial Ca 2+ (i.e. cytosolic) may play a role in the 4'I-MPP + accumulation. In addition, the mNCX inhibitors, CGP37157 [specific mNCX inhibitor [35, 36] ], KBR7943 [37] , and 2APB were also found to inhibit the uptake of 4'I-MPP + (Fig 6B; 50 M inhibitor at 200 M 4'I-MPP + ) into MN9D cells, while the specific mitochondrial Ca 2+ uniporter inhibitor, ruthenium red [38, 39] (~10% inhibition was observed at 10 M concentration), or voltage gated Ca 2+ channel inhibitors, verapamil [40] or benzamil [41, 42] pre-treatments significantly reduced the typical mitochondrial membrane depolarization seen with 4'I-MPP + in MN9D cells ( Fig 6E) . The experiments with the mitochondrial membrane potential sensitive fluorescent dye, TMRM, showed that CGP37157 slows down the 4'I-MPP + -induced mitochondrial membrane depolarization of HepG2 cells lasting at least 4 h ( Fig 6G) . The effect of extracellular Ca 2+ on the uptake of MPP + and 4'I-MPP + into MN9D cells was also examined using standard HPLC-UV techniques. These experiments have revealed that the omission of Ca 2+ from the incubation medium with the inclusion of a similar concentration of the Ca 2+ chelator, EGTA, increase the uptake of both toxins by about 3-4 folds ( Fig 6F) . 
mNCX inhibitors protect MN9D cells from MPP + and 4'I-MPP + toxicities
The inhibition of mitochondrial uptake of both MPP+ and 4'I-MPP + suggest that CGP37157 must also protect MN9D cells from the toxicities of both toxins. As shown from the data in presented as mean ± SD (n=6). *p<0.0001 and #p<0.005 versus no CGP37157 controls.
Discussion
The aim of this study was to characterize a structural and functional MPP + mimic, which is suitable to study the cellular distribution and mitochondrial uptake of MPP + in live cells and use it to identify the molecular details of these processes to advance the understanding of the mechanism of the selective dopaminergic toxicity of MPP + . Accordingly, we have characterized the fluorescent MPP + derivative, 4'I-MPP + , as a suitable candidate for this purpose with a number of promising characteristics. 4'I-MPP + which was synthesized in good yield using the previously described procedures, [15] showed a red shifted UV-Vis absorption band at ~313 nm (with respect to the characteristic UV-Vis band of MPP + at ~295 nm), and a moderately intense fluorescence band with the excitation and emission maxima at 320 and 430 nm in PBS, respectively. Neither the absorption band nor the fluorescence emission of 4'I-MPP + was significantly blue shifted upon increasing the polarity of the solvent, in contrast to the photophysical behaviors of previously described 4'-(dimethylamino)-and related MPP + derivatives [43, 44] . Similarly, the fluorescence Toxicity studies with dopaminergic MN9D [14] cells in reference to non-neuronal liver HepG2 (control) cells [46] have confirmed that 4'I-MPP + is selectively toxic to MN9D cells similar to MPP + . In addition, the complex-1 inhibition, cellular ATP depletion, and ROS production selectively in dopaminergic cells leading to apoptotic cell death are also common characteristics of both toxins. However, 4'I-MPP + was a stronger dopaminergic toxin and a complex-I inhibitor in comparison to MPP + under similar conditions, most likely due to its relatively higher cellular uptake and complex -I inhibition potency in comparison to MPP + . This notion is consistent with the previously reported relatively high complex-I inhibition potencies and dopaminergic toxicities of 4'-alky substituted lipophilic MPP + derivatives. [47, 48] In addition, the uptake time courses Although MPP + is shown to accumulate in the mitochondria isolated from different cell types, [18, 49] the molecular details of the mitochondrial accumulation of MPP + are not fully explored. While the mitochondrial accumulation of MPP + has not been directly demonstrated in live cells, the cellular and various intracellular organelle accumulation of fluorescent 4′-(dimethylamino)-MPP + and related derivatives in live cells have been previously reported [43] .
However, the use of these derivatives in the routine cellular or mitochondrial accumulation studies is limited by their nonspecific accumulation into the nucleoli and other organelles (in addition to the mitochondria), [43] interaction and inhibition of various cell membrane transporters, and ability to non-specifically bind to the cell and sub-cellular organelle membranes in large quantities [44, 50] . On the other hand, dual mitochondrial and 4'I-MPP + fluorescence imaging show that intracellular 4'I-MPP + is primarily localized into the mitochondria of the cell with only relatively small quantities are associated with the cell cytosol, nucleoli or the membrane (Fig 4A) .
Previous studies have suggested that the driving force for the mitochondrial accumulation of MPP + is the large inside negative inner mitochondrial membrane potential [30, 51] . The uptake of MPP + and 4'I-MPP + into isolated MN9D cell mitochondria using traditional HPLC-UV techniques show that the efficiency of 4'I-MPP + accumulation is significantly greater than that of MPP + , parallel to the trend that was observed for the cellular uptake. This difference is consistent with the membrane potential facilitated simple diffusion process (see below), since 4'I-MPP + is relatively more lipophilic in comparison to MPP + ( Table 1 ). As expected, the mitochondrial accumulation of 4'I-MPP + is associated with a significant depolarization of the mitochondrial membrane potential, as previously reported for MPP + [18] . Furthermore, the more lipophilic 4'I-MPP + is a more effective mitochondrial membrane potential depolarizing agent than MPP + , which is consistent with the relatively high mitochondrial uptake efficiency of 4'I-MPP + relative to MPP + .
These findings together with the observation that FCCP (a mitochondrial membrane depolarizing agent) inhibits the mitochondrial accumulation of intracellular 4'I-MPP + in MN9D and HepG2 cells, in comparison to the control cells, suggest the active mitochondrial accumulation of these toxins must be driven by a strong mitochondrial membrane potential energized, simple diffusion process. In addition, a significant decrease of the cellular accumulations of both MPP + and 4'I-MPP + in FCCP treated MN9D and HepG2 cells suggest that the effective mitochondrial uptake may also facilitate the cellular uptake of both toxins. Interestingly, HepG2 cell 4'I-MPP + uptake is consistently and significantly more sensitive to FCCP treatments in comparison to MN9D cells.
Although the origin of this difference between MN9D and HepG2 cells are not fully understood at present, these findings are in good agreement with a process in which the mitochondrial uptake of MPP + and 4'I-MPP + is a membrane potential facilitated diffusion process in both cell types and the cellular uptakes could be coupled to the mitochondrial uptakes efficiencies at least under in vitro conditions. depleted mitochondria take up more MPP + than Ca 2+ loaded mitochondria [34] . To model the role of Ca 2+ in MPP + uptake, the mimic, 4'I-MPP + , was used based on the rational that it will produce a clearer picture, due to its relatively high rate of mitochondrial uptake in comparison to MPP + .
The isolated MN9D cell mitochondrial 4'I-MPP + uptake is inhibited by extra-mitochondrial Ca 2+ at physiologically relevant 500-1000 nM concentrations ( Fig 6A) . More intriguingly, 4'I-MPP + uptake into the mitochondria is also effectively inhibited by mNCX inhibitors CGP37157, KBR7943 and 2APB in a dose dependent manner at pharmacologically relevant concentrations ( Fig 6B and 6C ). In addition, CGP37157 also prevents the mitochondrial localization of intracellular 4'I-MPP + under the cellular conditions ( Fig 6D) . In agreement with these findings, CGP37157 also inhibits the characteristic mitochondrial membrane depolarization by 4'I-MPP + in a concentration dependent fashion. These findings suggest that cytosolic/mitochondrial Ca 2+ play a role in mitochondrial accumulation of these toxins and that this role is likely to be mediated through mNCX. Although, the exact roles of mNCX/Ca 2+ in cellular/mitochondrial uptake of these toxins are not fully understood at present, repolarization of the toxin depolarized mitochondrial membrane by the efflux of Ca 2+ through mNCX facilitating the continued electogenic uptake of MPP + or 4IMPP + could be a likely possibility. The observed substantial increase of cellular uptake of both MPP + and 4'I-MPP + into MN9D cells (2 to 3-fold) in Ca 2+ free, EGTA containing media further suggest that extrusion of the cytosolic Ca 2+ through plasma membrane NCX may also facilitate the continued uptake of these toxins. These possibilities are in good agreement with the above suggestion that mitochondrial and cellular uptakes of MPP + and 4'I-MPP + are coupled. Since mitochondrial accumulation and the complex-I inhibition mediated increase of ROS production is intimately associated with the MPP + and 4'I-MPP + -mediated apoptotic MN9D cell death, [18, 52] the inhibition of mitochondrial uptake by CGP37157 was expected to protect MN9D cells from of these toxins. As expected, CGP37157 effectively protected MN9D cells from both MPP + and 4'I-MPP + toxicities (Fig 7) . These findings suggest that in addition to mitochondrial accumulation, complex-I inhibition, and ATP depletion MPP + and related mitochondrial toxins may also exert their toxic effects through the perturbation of Ca 2+ homeostasis in dopaminergic cells. However additional studies are certainly necessary to fully describe the effect of Ca 2+ on the cellular and mitochondrial uptake and toxicities of MPP + and related toxins. Similarly, to firmly establish the physiological significance of these findings, these in vitro cell model finding must be confirmed in physiologically more relevant in vitro and in vivo model systems.
Taken together, the above findings demonstrate that the unique chemical and photophysical characteristics of 4'I-MPP + together with the its superior uptake and toxicological characteristic relative to MPP + make it a valuable tool to further investigate the mechanism(s) of the selective dopaminergic cell toxicity of MPP + and similar toxins in live cell and animal models. The intrinsic fluorescence of 4'I-MPP + under physiological conditions could also be used to map the cellular distribution of the toxin in the CNS of animal models. The novel finding that cytosolic/mitochondrial Ca 2+ play a critical role in the mitochondrial and cellular accumulation apparently through NCX is intriguing and suggest for the first time that MPP + and related mitochondrial toxins may also exert their toxic effects through the perturbation of Ca 2+ homeostasis in dopaminergic cells. Finally, the discovery that specific mNCX inhibitors protect dopaminergic cells from the MPP + toxicity, presumably through the inhibition of the mitochondrial uptake, could potentially be further exploited for the development of pharmacological agents to protect the CNS dopaminergic system from PD-causing environmental toxins. RR016475] (to KW).
